Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations

ABSTRACT Given the limitations of current antileishmanial drugs and the utility of oral combination therapy for other infections, developing an oral combination against visceral leishmaniasis should be a high priority. In vitro combination studies with DB766 and antifungal azoles against intracellular Leishmania donovani showed that posaconazole and ketoconazole, but not fluconazole, enhanced DB766 potency. Pharmacokinetic analysis of DB766-azole combinations in uninfected Swiss Webster mice revealed that DB766 exposure was increased by higher posaconazole and ketoconazole doses, while DB766 decreased ketoconazole exposure. In L. donovani-infected BALB/c mice, DB766-posaconazole combinations given orally for 5 days were more effective than DB766 or posaconazole alone. For example, 81% ± 1% (means ± standard errors) inhibition of liver parasite burden was observed for 37.5 mg/kg of body weight DB766 plus 15 mg/kg posaconazole, while 37.5 mg/kg DB766 and 15 mg/kg posaconazole administered as monotherapy gave 40% ± 5% and 21% ± 3% inhibition, respectively. Combination index (CI) analysis indicated that synergy or moderate synergy was observed in six of nine combined dose groups, while the other three were nearly additive. Liver concentrations of DB766 and posaconazole increased in almost all combination groups compared to monotherapy groups, although many increases were not statistically significant. For DB766-ketoconazole combinations evaluated in this model, two were antagonistic, one displayed synergy, and one was nearly additive. These data indicate that the efficacy of DB766-posaconazole and DB766-ketoconazole combinations in vivo is influenced in part by the pharmacokinetics of the combination, and that the former combination deserves further consideration in developing new treatment strategies against visceral leishmaniasis.

[1]  Michael J. Dagley,et al.  High-content assay for measuring intracellular growth of Leishmania in human macrophages. , 2015, Assay and drug development technologies.

[2]  Xiaohua Zhu,et al.  SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines. , 2015, Bioorganic & medicinal chemistry.

[3]  W. de Souza,et al.  Potent In Vitro Antiproliferative Synergism of Combinations of Ergosterol Biosynthesis Inhibitors against Leishmania amazonensis , 2015, Antimicrobial Agents and Chemotherapy.

[4]  M. Gicheru,et al.  In vitro activity and in vivo efficacy of a combination therapy of diminazene and chloroquine against murine visceral leishmaniasis , 2015, Journal of biomedical research.

[5]  S. Sundar,et al.  An update on pharmacotherapy for leishmaniasis , 2015, Expert opinion on pharmacotherapy.

[6]  M. Ghannoum,et al.  Multilaboratory Testing of Antifungal Drug Combinations against Candida Species and Aspergillus fumigatus: Utility of 100 Percent Inhibition as the Endpoint , 2014, Antimicrobial Agents and Chemotherapy.

[7]  O. Cenciarelli,et al.  Synergistic Effect of Nitazoxanide with Neuraminidase Inhibitors against Influenza A Viruses In Vitro , 2014, Antimicrobial Agents and Chemotherapy.

[8]  F. Buckner,et al.  Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi , 2014, PLoS neglected tropical diseases.

[9]  Thomas D. Schmittgen,et al.  Studies on the Antileishmanial Mechanism of Action of the Arylimidamide DB766: Azole Interactions and Role of CYP5122A1 , 2014, Antimicrobial Agents and Chemotherapy.

[10]  D. Kyle,et al.  Antileishmanial Activity of a Series of N2,N4-Disubstituted Quinazoline-2,4-diamines , 2014, Journal of medicinal chemistry.

[11]  D. Boykin,et al.  Pharmacokinetic Comparison To Determine the Mechanisms Underlying the Differential Efficacies of Cationic Diamidines against First- and Second-Stage Human African Trypanosomiasis , 2014, Antimicrobial Agents and Chemotherapy.

[12]  B. McGwire,et al.  Voriconazole suppresses the growth of Leishmania species in vitro , 2013, Parasitology Research.

[13]  D. Boykin,et al.  Antileishmanial bis-arylimidamides: DB766 analogs modified in the linker region and bis-arylimidamide structure-activity relationships. , 2012, Bioorganic & medicinal chemistry letters.

[14]  W. Wilson,et al.  Synthesis, DNA binding and antileishmanial activity of low molecular weight bis-arylimidamides. , 2012, European journal of medicinal chemistry.

[15]  A. Genovesio,et al.  An Image-Based High-Content Screening Assay for Compounds Targeting Intracellular Leishmania donovani Amastigotes in Human Macrophages , 2012, PLoS neglected tropical diseases.

[16]  A. Hailu,et al.  Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial , 2012, PLoS neglected tropical diseases.

[17]  W. Wilson,et al.  Evaluation of Arylimidamides DB1955 and DB1960 as Candidates against Visceral Leishmaniasis and Chagas' Disease: In Vivo Efficacy, Acute Toxicity, Pharmacokinetics, and Toxicology Studies , 2012, Antimicrobial Agents and Chemotherapy.

[18]  Xiaohua Zhu,et al.  Identification of New Antileishmanial Leads from Hits Obtained by High-Throughput Screening , 2011, Antimicrobial Agents and Chemotherapy.

[19]  C. Shaha,et al.  CYP5122A1, a Novel Cytochrome P450 Is Essential for Survival of Leishmania donovani , 2011, PloS one.

[20]  W. Wilson,et al.  Molecular factors governing inhibition of arylimidamides against Leishmania: conservative computational modeling to improve chemotherapies. , 2011, Bioorganic & medicinal chemistry.

[21]  W. Haq,et al.  CpG Oligodeoxynucleotide 2006 and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis , 2011, Antimicrobial Agents and Chemotherapy.

[22]  S. Sundar,et al.  Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial , 2011, The Lancet.

[23]  G. Schoenian,et al.  Successful Treatment of Old World Cutaneous Leishmaniasis Caused by Leishmania infantum with Posaconazole , 2011, Antimicrobial Agents and Chemotherapy.

[24]  R. Madhubala,et al.  Novel Arylimidamides for Treatment of Visceral Leishmaniasis , 2010, Antimicrobial Agents and Chemotherapy.

[25]  P. Gershkovich,et al.  Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. , 2009, The Journal of infectious diseases.

[26]  Xiaohua Zhu,et al.  Redox-active dinitrodiphenylthioethers against Leishmania: synthesis, structure-activity relationships and mechanism of action studies. , 2009, Bioorganic & medicinal chemistry.

[27]  M. Rai,et al.  New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  L. Cowen,et al.  Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance , 2008, Eukaryotic Cell.

[29]  Shujuan Sun,et al.  In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves. , 2008, The Journal of antimicrobial chemotherapy.

[30]  J. Heitman,et al.  Synergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Biofilms , 2008, Antimicrobial Agents and Chemotherapy.

[31]  Ting-Chao Chou,et al.  Preclinical versus clinical drug combination studies , 2008, Leukemia & lymphoma.

[32]  D. Boykin,et al.  CYP4F Enzymes Are the Major Enzymes in Human Liver Microsomes That Catalyze the O-Demethylation of the Antiparasitic Prodrug DB289 [2,5-Bis(4-amidinophenyl)furan-bis-O-methylamidoxime] , 2006, Drug Metabolism and Disposition.

[33]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[34]  R. Stahlmann,et al.  Drug interactions during therapy with three major groups of antimicrobial agents , 2006, Expert opinion on pharmacotherapy.

[35]  S. Croft,et al.  In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs , 2006, Antimicrobial Agents and Chemotherapy.

[36]  F. Buckner,et al.  Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages. , 2005, The American journal of tropical medicine and hygiene.

[37]  C. Banfield,et al.  Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[38]  F. Odds,et al.  Synergy, antagonism, and what the chequerboard puts between them. , 2003, The Journal of antimicrobial chemotherapy.

[39]  D. Sanglard,et al.  Potent Synergism of the Combination of Fluconazole and Cyclosporine in Candida albicans , 2000, Antimicrobial Agents and Chemotherapy.

[40]  Joseph Heitman,et al.  Synergistic Antifungal Activities of Bafilomycin A1, Fluconazole, and the Pneumocandin MK-0991/Caspofungin Acetate (L-743,873) with Calcineurin Inhibitors FK506 and L-685,818 against Cryptococcus neoformans , 2000, Antimicrobial Agents and Chemotherapy.

[41]  D. Loebenberg,et al.  Efficacy of the Triazole SCH 56592 againstLeishmania amazonensis and Leishmania donovani in Experimental Murine Cutaneous and Visceral Leishmaniases , 1999, Antimicrobial Agents and Chemotherapy.

[42]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[43]  F. Derouin,et al.  Experimental Evaluation of Second-Line Oral Treatments of Visceral Leishmaniasis Caused by Leishmania infantum , 1999, Antimicrobial Agents and Chemotherapy.

[44]  S. Sundar,et al.  Treatment of kala-azar with oral fluconazole , 1996, The Lancet.

[45]  H. Murray,et al.  Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis , 1996, Antimicrobial agents and chemotherapy.

[46]  G. Kirigi,et al.  The efficacy and safety of ketoconazole in visceral leishmaniasis. , 1994, East African medical journal.

[47]  B L Robinson,et al.  The chemotherapy of rodent malaria. XLV. Reversal of chloroquine resistance in rodent and human Plasmodium by antihistaminic agents. , 1990, Annals of tropical medicine and parasitology.

[48]  D. Beach,et al.  Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. , 1988, Molecular and biochemical parasitology.

[49]  H. Masur,et al.  Cell-mediated immune response in experimental visceral leishmaniasis. I. Correlation between resistance to Leishmania donovani and lymphokine-generating capacity. , 1982, Journal of immunology.

[50]  T. Chou,et al.  Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method. , 2016, American journal of cancer research.